ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nalbuphine

Also written as “NAL ER”, “nalbuphine HCl ER” and “Nalbuphine Hydrochloride Injection”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Prurigo · Pruritus · Chronic Cough · Opioid-Related Disorders, led by 4 companies.

Drug pageNalbuphine: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 17, 201421 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Trevi Therapeuticsits history only184 open or runningphase 3since May 17, 2014May 17, 2014Nov 30, 2026phase 1 · NCT07946575
Lumosa Therapeuticsits history only10 open or runningphase 1since May 13, 2015May 13, 2015none ahead
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceuticalits history only10 open or runningphase 3since Apr 1, 2025Apr 1, 2025none ahead
Yung Shin Pharm. Ind.10 open or runningphase 4since Jan 27, 2019Jan 27, 2019none ahead

Also a collaborator on its studies: Parexel and Davita Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named nalbuphineINNProposed as its International Nonproprietary Name in WHO's List 114
  2. Jan 27, 2019First study: phase 4 study in Pain, PostoperativeFirst studyNCT03826316 · 14 enrolled · Taiwan

TargetBeta

“Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
cebranopadolruleTris Pharmaphase 318

Studies

The one study Yung Shin Pharm. Ind. leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03826316Pain, Postoperative · Taiwan4CompletedNov 22, 201814

How it is read

Names in the registry

  • “NAL ER”, 12 entries
  • “nalbuphine HCl ER”, 2 entries
  • “Nalbuphine Hydrochloride Injection”, 1 entry
  • “Nalbuphine ER”, 1 entry
  • “Nalbuphine ER Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.